PR Newswire
11 Jun 2022, 05:15 GMT+10
PROVIDENCE, R.I., June 11, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National Institutes of Health (SBIR grant #R43AI058376). The company is looking for a strategic partner with funding and experience in advanced preclinical development and clinical trials to move this "Epitope-Driven Vaccine" into clinical trials. Although the U.S. government has stockpiled two vaccinia virus vaccines for both smallpox and monkeypox, a next generation subunit vaccine may offer a dose-sparing strategy that increases availability of one of the vaccines and avoids safety risks of the other.
Experts in T cell biology, EpiVax scientists have been developing novel T cell epitope vaccines since the company was founded in 1998. This vaccine is named VennVax because it was developed by defining conserved elements between vaccinia (the cowpox virus) and smallpox (the disease that vaccinia vaccine protects against). These conserved elements (T cell epitopes) are also conserved in monkeypox. Initial studies in HLA transgenic mice demonstrated 100% survival rates.
EpiVax has also marked progress this year on a new vaccine for avian influenza that incorporates an immune-engineered H7N9 Hemagglutinin (HA) vaccine antigen, which increased the immunogenicity and efficacy in mouse models. Publication forthcoming in an upcoming 2022 issue of Human Vaccines & Immunotherapeutics. This follows promising results for a Q Fever T cell vaccine candidate published in Frontiers in Immunology in May 2022, in collaboration with Massachusetts General Hospital Scientists.
Dr. Lenny Moise, Director of Vaccine Research at EpiVax had this to say on the potential of T cell vaccine technology: "We are optimistic about the future for vaccines designed to exploit T cell immunity. Our T cell-directed smallpox vaccine shows it's possible to fully protect against disease without inducing an antibody response. And when antibodies are needed, whole antigens can be sculpted to trigger stronger T cell responses for increased vaccine efficacy."
EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's screening toolkits for therapeutics and vaccines are employed in advancing the research of a global roster of companies.
For more information, visit www.epivax.com.
Press Contact:
Katie Porter, Business Development Manager
EpiVax
kporter@epivax.com
SOURCE EpiVax Inc.
Get a daily dose of Malaysia Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Malaysia Sun.
More InformationSHAN STATE, Myanmar - Locals claim that the Pa-O National Organisation (PNO) militia has been forcibly recruiting members from villages ...
DHAKA, Bangladesh - The Haji Yunus Ali School and College in Ashulia, Savar, has suspended a student hanging out with ...
KATHMANDU, Nepal - According to the Department of Forests and Soil Conservation, 90 settlements in Salyan are at high risk ...
LAHORE, Pakistan - FIFA, the world governing body of football, lifted Pakistan's suspension on Thursday and extended the mandate of ...
MANDALAY, Myanmar - On Wednesday, Junta authorities arrested three more Mandalay-based lawyers representing political detainees after leaving their clients' hearings ...
DHAKA, Bangladesh - Tarique Rahman's support for Bangabandhu Sheikh Mujib's killers has been criticized by Sheikh Hasina. The murderers of ...
SYDNEY, NSW, Australia - Stocks in Asia generally moved higher on Monday despite continuing concerns over a potential global recession.U.S. ...
WASHINGTON D.C.: Due to surging food prices, summer cookouts for the U.S. Independence Day holiday are more expensive, forcing Americans ...
WASHINGTON D.C.: In a cardboard box factory outside Baltimore, people have been walking into the office of Paul Centenari, chief ...
DELFT, Netherlands: IKEA officials said this week that the furniture retailer's warehouses in Europe are as full as they were ...
NEW YORK CITY, New York: After the first six months of 2022, the S&P 500 recorded a loss of 20.6 ...
WASHINGTON D.C.: Due to the record high trade deficit and a resurgence in COVID-19 infections that curbed spending on services, ...